---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-047460"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:40:09.025674+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CytomX restates 2018-2021 annual and 2018-2022 quarterly financials due to revenue recognition error

## Summary
- Restatement affects timing of revenue from collaborations with Bristol-Myers Squibb, Astellas, AbbVie, and Amgen.
- No impact on total revenue, cash position, or cash flows; only timing of revenue recognition changes.
- Material weakness identified in internal control over financial reporting related to ASC 606 application.
- Company plans to amend 2021 Form 10-K and restate 2021 and 2022 quarters in 2022 Form 10-K.

## SEC filing metadata
- accession: 0001193125-23-047460
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312523047460/0001193125-23-047460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312523047460/d414055d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-047460
- JSON: https://secwatch.observer/filing/0001193125-23-047460.json
- Plain text: https://secwatch.observer/filing/0001193125-23-047460.txt

## Key facts
- Auditor Changes
  CytomX Therapeutics, Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  - Auditor: Ernst & Young LLP
  source text: determined that the Company's financial statements and related earnings press releases for the years ended December 31, 2018, 2019, 2020 and 2021, and each of the previously reported quarters from 2018 through 2022 (the “Restated Periods”), should no longer be relied upon.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312523047460/0001193125-23-047460-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.